AIScientific modelsStory 05
A biology model leaves research preview
What changedOpenAI moved GPT-Rosalind out of research preview and made it globally available to eligible organizations through a trusted-access program, with published pricing due October 5. Qualified labs gain a model aimed at chemistry, proteins, genomics and tool-heavy workflows. Evidence of performance remains mostly OpenAI-reported, and this access change is not a drug discovery.
The useful part
Why it matters
A specialized research model is moving from a small preview into controlled organizational use, giving more laboratories a concrete access and pricing path.
Worth doing
What to do next
Evaluate one bounded evidence-synthesis or analysis workflow with human review before putting the model near experimental decisions.
Keep in mind
Good to know
Access remains gated to approved organizations, and most capability evidence comes from OpenAI and selected partners.
Evidence